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the Medicare prescription drug program provided this vulnerable
population with an important new source of drug coverage.
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OBJECTIVE: Drug-drug interactions (DDI) have been well asso-
ciated with signiﬁcant medical, safety, and economic conse-
quences, particularly in older and chronically ill patients. This
study examined several aspects of medication safety by quanti-
fying and proﬁling the prevalence, population exposure, and
characteristics of clinically signiﬁcant DDIs among Medicare
Part D utilizing beneﬁciaries. Lumetra and six California Medi-
care Advantage prescription drug plans (MAPD) and stand-alone
prescription drug plans (PDP) will collaboratively utilize results
to design effective quality improvement initiatives to minimize
adverse clinical outcomes due to these DDI’s. METHODS: This
study assessed the prevalence and population exposure of DDIs
among Medicare and dual eligible (i.e., Medicare +Medi-caid
status) beneﬁciaries enrolled across six of California’s Part D
MAPD and PDPs. Retrospective, cross sectional pharmacy
claims data from January 1, 2006 through December 31, 2006
were analyzed to obtain the frequency of drug interactions that
are clinically signiﬁcant and well-documented in the medical and
pharmacy literature. RESULTS: The analysis included 368,607
utilizing beneﬁciaries. The overall prevalence rate of DDI was
5.9%. The number of clinically signiﬁcant DDI cases was 7962
per 100,000 beneﬁciaries. Stratiﬁed analyses indicated that males
and older beneﬁciaries appear to be at a higher risk of incurring
a clinically signiﬁcant DDI. Risk of a DDI also increased as the
number of unique medications and/or number of prescribing
physicians increased per enrollee. CONCLUSION: The preva-
lence and characteristics of clinically signiﬁcant DDIs among
California elderly and chronically ill patients were positively
associated with certain demographic factors and health care
resource utilization proﬁles. Stratifying high-risk individuals with
discrete or multiple DDI’s will enable Part D MAPDs and PDPs
to perform in-depth case management in targeted individuals.
Point-of-service edits and information obtained from retrospec-
tive drug claims review can be used in conjunction to customize
meaningful intervention strategies.
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OBJECTIVE: To measure the impact of improvements in access
to care on Medicare spending growth for diagnostic imaging (DI)
services. METHODS: We modeled Medicare DI spending growth
as a function of growth in: enrollment; per-service payment;
access to care (% using  1 service); volume (services/user); and
intensity (relative value units per service used). We then used
Medicare Standard Analytic File 5% sample data from 2002–
2005 to decompose DI spending growth into these factors by
modality: standard (x-ray and ultrasound); and advanced (com-
puted tomography (CT), magnetic resonance (MR) and nuclear).
RESULTS: Aggregate DI service spending grew at an annual rate
of 15.2% during 2002–2005, and varied substantially by modal-
ity (x-ray 10.2%, ultrasound 11.7%, CT 19.6%, MR 18.5%,
nuclear 15.0%). Enrollment growth accounted for less than 15%
of this increase (range: 7.2% (CT)—13.3% (x-ray)), while the
impact of payment increases was far greater and varied widely
(range: 7.6% (nuclear)—54.0% (x-ray)). The share of DI spend-
ing growth attributable to improvements in access to care was:
x-ray (6.5%); ultrasound (19.1%); CT (30.4%); MR (49.0%);
and nuclear (30.5%). The contribution of volume growth to
overall spending growth ranged from 10.5% for MR to 24.1%
for CT. Service intensity growth accounted for less than 10% of
spending growth for x-ray, CT and MR; 17.9% and 33.0% of
spending growth for ultrasound and nuclear were due to service
intensity growth, respectively. CONCLUSION: Improved access
to care explains approximately 30%–50% of the growth in
Medicare spending for advanced diagnostic imaging services.
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OBJECTIVE: In early 2006, 18,820 vulnerable Medicare beneﬁ-
ciaries with RA or MS participating in a biologic drug demon-
stration program (MRDD) transitioned into Medicare Part D
plans. We compared the types of biologic drug coverage offered
by Part D plans. METHODS: We examined Part D plans’ cost
structure (e.g. premium, deductible, cost sharing) for the spe-
cialty biologic drugs offered during the MRDD: adalimumab,
etanercept, anakinra (for RA), interferon beta 1a and 1b, glati-
ramer acetate, and HP acthar gel (for MS). For MRDD and Part
D plans, we compared beneﬁciaries’ average out-of-pocket costs
(OOPC). RESULTS: Beneﬁciaries enrolled in 1061 stand-alone
(SA) and 705 Medicare Advantage (MA) Part D plans. All SA
plans and all but one MA plan covered etanercept, interferon
beta 1b, and glatiramer acetate. The proportion covering the
other drugs varied between 38–92%. MA plans were more likely
to cover anakinra, interferon beta 1a, and HP acthar gel than SA
plans (p < 0.05). All plans used co-insurance as the preferred
form of cost sharing; average co-insurance ranged from 25–31%
of the drug price. The majority of plans assumed >75% of the
cost sharing for each drug dispensing during the initial coverage
period, but only 2% of plans offered coverage during the cover-
age gap. On average, beneﬁciaries’ OOPC were greater under
Part D than the standard beneﬁt-structured MRDD. Patients
with a MRDD subsidy were signiﬁcantly less likely to receive a
Part D subsidy (p < 0.0001), because assets were considered in
addition to income in the granting of subsidies under Part D.
CONCLUSION: Many Part D plans assume some costs for
specialty biologic drugs to treat RA and MS. Beneﬁciaries still
ﬁnd themselves facing high OOPC due to drug price, plans’
preference for co-insurance, and scant coverage during the
coverage gap.
PHP24
THE IMPACT OF BENEFIT PLAN DESIGN ON COST AND
HEALTH OUTCOMES
Chin W1, Bonnett C2, Jorch U3
1Ilex Consulting,Toronto, ON, Canada, 2H3 Consulting,Toronto, ON,
Canada, 3Jorch Consulting,Toronto, ON, Canada
OBJECTIVE: When private payers implement changes to control
health beneﬁt costs, the longer term consequences may not be
considered. The aim was to identify scientiﬁc studies that exam-
Abstracts A35
ined the impact of changes in private drug plan formulary design
on the health of private plan beneﬁciaries. METHODS: A search
of the medical literature was conducted using the PubMed search
engine. Search terms included combinations of reimbursement,
formulary, plan, payer, restriction, cost, and adherence. The
‘related articles’ feature in PubMed was also used to identify
relevant papers. RESULTS: While no published studies of Cana-
dian employer-sponsored drug plans were identiﬁed, there were
15 North American studies that focused on the effects of changes
in drug plan design. This body of research demonstrated three
key points. Cost-sharing initiatives resulted in a reduction, or
complete cessation, of medication consumption, including
drugs deemed “essential”, and that decreased adherence to drug
therapy can actually lead to the increased use of other more
expensive health care resources. On the other hand, higher levels
of medication adherence, which increased drug costs, were asso-
ciated with lower overall health care costs. Employee satisfaction
with their employer drug plan decreased when cost-containment
measures were implemented and this is a problem for employers
since drug plan changes typically involved increasing fees or
imposing more restrictions to access. CONCLUSION: A short-
term focus on controlling drug costs is likely to have negative
consequences on the health, productivity and satisfaction of plan
members. If changes to drug plans are not properly assessed,
there can be undesirable and expensive consequences for plan
members and employers. Employers need a longer term frame-
work to guide and support health plan decision-making that
avoids sudden or drastic changes to health beneﬁts. Careful
consideration of drug plan design and cost-sharing can improve
medication adherence, health outcomes, employee satisfaction,
and costs.
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OBJECTIVES: While pharmaceuticals can signiﬁcantly improve
the health of patients and help to mitigate health-related inequi-
ties within a population, their rising prominence within health
systems is not without challenges. This paper explores health
related aspects of pharmaceutical policy in Australia, Canada,
Germany, The Netherlands, New Zealand, the UK and the
United States. METHODS: Drawing on published goals for
national policies, we developed a framework for gauging
pharmacare system performance. We review policy structures
and investigate system performance using preliminary indicators
drawn from the 2007 Commonwealth Fund Survey. Survey
responses to questions related to accessibility, affordability, and
appropriateness are compared across countries and stratiﬁed by
age, income and morbidity. RESULTS: Shares of populations
reporting prescription drug use were lowest in Germany and
highest in the US. Pharmaceutical use displayed expected age
gradients in all countries and expected income gradients in all but
Germany and the US. Cost-related non-adherence was most fre-
quent in the US and Australia, and relatively unlikely among
elderly populations. Relatively few patients reported prescribing
errors, with no signiﬁcant differences across countries. Out-of-
pocket drug costs were highest in the US and Canada. From 1995
to 2005, pharmaceutical expenditures outpaced health care and
GDP in all countries except New Zealand. Expenditure grew
most quickly in the US. CONCLUSION: Though no country
appears uniformly strong in all areas of pharmacare policy,
several appear to have done well to manage difﬁcult tensions in
the pharmaceutical sector.
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OBJECTIVE: Snyder and King (2007) developed a theoretical
model of ﬁrm behavior in which research and marketing activi-
ties are complements rather than substitutes. Public policy debate
frequently makes the implicit assumption that the two activities
are substitutes. In this paper the author uses ﬁnancial reports of
Fortune 200 pharmaceutical ﬁrms to examine the evidence for
Snyder and King’s theoretical model. METHODS: We extract
research and marketing expenditure totals from the quarterly
ﬁlings of the eight largest U.S. based pharmaceutical companies.
We also create a comparator list of non-pharmaceutical compa-
nies matched for size and using pre-speciﬁed exclusion criteria.
Univariate analysis is used to test whether pharmaceutical
companies are systematically different from the comparator com-
panies. Simple regression analysis is used to test whether com-
panies with higher research/revenue ratios have higher or lower
marketing/revenue ratios. RESULTS: Pharmaceutical ﬁrms spend
a greater share of revenue on both marketing and R&D than the
comparator ﬁrms. The share spent on marketing is similar to a
subgroup of the comparator ﬁrms. The share spent on research
is uniquely high. Pharmaceutical ﬁrms are also unique in their
combination of high marketing and high research spending.
Regression analysis shows no signiﬁcant relationship (positive or
negative) between research and marketing expenditure. CON-
CLUSION: Empirical analysis provides limited support to the
theory developed in Snyder and King (2007). The absence of
signiﬁcant regression results may be due to the time lag between
development and approval for sale.
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OBJECTIVE: The RIZIV/INAMI, the Belgian third-party payer,
aims to set reimbursement tariffs at a level that reﬂects costs of
orthotic braces. In the absence of publicly disclosed information
on the cost structure of braces, estimating production and distri-
bution costs of braces is valuable to reimbursement agencies with
a view to setting tariffs. The aim of this study is to calculate the
cost of production and distribution of a prefabricated hard neck
brace and a prefabricated hard knee brace, and to explore
whether Belgian tariffs and actual retail prices correspond with
estimated costs of these two braces. METHODS: The cost model
took into account manufacturing costs, general overhead,
research and development, warehousing, proﬁt and distribution
margins. Data were gathered from manufacturers, a visit to a
production site, desk research, a decomposition of ﬁnished prod-
ucts and interviews with stakeholders. The price year was 2007.
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